Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

• ClinicalTrials.gov Identifier: NCT01095003
• Recruitment Status: Completed
• First Posted: March 29, 2010
• Results First Posted: September 13, 2019
• Last Update Posted: April 28, 2022
• Sponsor: Pierre Fabre Medicament
• Information provided by (Responsible Party): Pierre Fabre Medicament

Tracking Information

• First Submitted Date: March 24, 2010
• First Posted Date: March 29, 2010
• Results First Submitted Date: May 27, 2019
• Results First Posted Date: September 13, 2019
• Last Update Posted Date: April 28, 2022
• Study Start Date: May 2009
• Actual Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 7, 2019)

Progression Free Survival [ Time Frame: Baseline up to 2 years 7 months ]

PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause. The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.

• Original Primary Outcome Measures (submitted: March 26, 2010): Progression Free Survival [ Time Frame: Every 6 weeks ]

Current Secondary Outcome Measures (submitted: August 7, 2019)

• Overall Survival [ Time Frame: Baseline upto 3 years 10 months ]
  The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.
• Overall Response Rate (ORR) [ Time Frame: Baseline upto 2 years 7 months ]
  ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.
• Disease Control Rate [ Time Frame: Baseline up to 2 years 7 months ]
  Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.
• Duration of Response [ Time Frame: Baseline up to 2 years 7 months ]
  Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.

Original Secondary Outcome Measures (submitted: March 26, 2010)

• Overall Survival [ Time Frame: Every 6 months after disease progression ]
• Overall Response Rate & Disease Control Rate [ Time Frame: Every 6 weeks ]
• Adverse event profile [ Time Frame: Every 3 weeks ]
  Collection and grading of reported adverse events and laboratory abnormalities.
• Quality of Life [ Time Frame: Every 2 cycles (6 weeks) ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
• Official Title: A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
• Brief Summary: The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents. Options for the treatment of patients who have progressed after an anthracycline and a taxane are limited. The high level of in-vitro synergy of vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the encouraging response rate observed while combining IV vinflunine to oral capecitabine make it a promising combination to investigate further in a phase III trial. This phase III trial will evaluate the effectiveness and the safety profile of such combination for the treatment of patient with advanced breast cancer previously treated with or resistant to anthracycline and taxane resistant.

Detailed Description

This multicentre, open-label, randomised, Phase III study will enrol 764 patients with advanced breast cancer who have previously been treated with or are resistant to an anthracycline and who are taxane resistant. Patients will be randomised in a 1:1 ratio to receive vinflunine plus capecitabine (Arm A) or capecitabine alone (Arm B).

Randomisation will be stratified according to a minimization procedure:

1. Resistance to anthracyclines ("yes" versus "no"), Relapse ≤ 12 months in the adjuvant or neoadjuvant setting or progression ≤ 4 months in the metastatic setting,
2. Karnofsky performance status ("90-100" versus "70-80"),
3. Measurable disease ("yes" versus "no"),
4. The number of prior lines of chemotherapy in the metastatic setting ("0" versus "1" versus "> 1") and,
5. Study site.

Patients randomised in Arm A will receive:

• Vinflunine at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute i.v. infusion and,
• Capecitabine which will be self-administered by the patient in an outpatient setting. Patients will take 825 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.

For patients randomised in Arm B, capecitabine will be self administered by the patient in an outpatient setting. Patients will take 1250 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.

The doses and timing of treatment will be modified based on toxicities experienced by the patient.

Patients will be assessed for toxicity, tumour response and progression at regular intervals during treatment. Patients will be evaluated for safety if they received any study drug. Laboratory values, adverse events and other symptoms will be graded.

Tumour response, progression-free survival and duration of response will be evaluated for all randomised patients. Tumour assessment is to be performed every 6 weeks (+/- 3 working days) from randomisation (regardless of the timing of treatment cycles) until disease progression is documented. Patients who discontinue protocol treatment for reasons other than disease progression will have tumour assessments every 6 weeks until documented disease progression. Patients may continue to receive additional cycles of therapy until progressive disease or intolerable toxicity.

Quality of Life assessment, will be measured by EORTC QLQ-C30 and QLQ-BR23 questionnaires, which will be completed by patients.

The primary endpoint for the trial is progression free survival calculated from the date of randomization until the date of progression or the date of death whatever the reason of death. The analysis of Progression-Free Survival is planned to take place when 615 progressions or deaths have been observed. One interim safety analysis is planned and will take place when 50 patients of each arm have completed at least one cycle of study treatment. It is anticipated that up to 170 active study centres will participate, and that accrual will be completed in approximately 30 months.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Breast Cancer

Intervention

• Drug: Vinflunine plus Capecitabine

  Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks

  Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks

  Other Names:

  • JAVLOR
  • L00070 IN
• Drug: Capecitabine
  Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
  Other Name: XELODA

Study Arms

• Experimental: Vinflunine plus Capecitabine

  Patients received (in combination with capecitabine)

  • Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.

  Intervention: Drug: Vinflunine plus Capecitabine
• Active Comparator: Capecitabine single-agent
  Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
  Intervention: Drug: Capecitabine

• Publications *: Martin M, Campone M, Bondarenko I, Sakaeva D, Krishnamurthy S, Roman L, Lebedeva L, Vedovato JC, Aapro M. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Ann Oncol. 2018 May 1;29(5):1195-1202. doi: 10.1093/annonc/mdy063.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: November 22, 2011): 770
• Original Estimated Enrollment (submitted: March 26, 2010): 764
• Actual Study Completion Date: October 2015
• Actual Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• female patients
• 21 years of age or older
• histologically/cytologically confirmed carcinoma of the breast
• documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy
• either one, two or three prior chemotherapy regimens
• prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs
• measurable or non-measurable disease according to RECIST 1.1
• Karnofsky performance score of at least 70 %
• adequate haematological, hepatic and renal functions
• ECG without clinically relevant abnormality

Exclusion Criteria:

• known or clinical evidence of brain metastasis or leptomeningeal involvement
• pulmonary lymphangitis or symptomatic pleural effusion
• any serious, concurrent uncontrolled medical disorder
• history of second primary malignancy
• preexisting motor/sensory peripheral neuropathy
• known history of HIV infection
• prior therapy with capecitabine and/or vinca-alkaloids
• history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs
• known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
• pregnancy or breast feeding

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 21 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Argentina, Belarus, Belgium, Brazil, Bulgaria, Czechia, Estonia, France, Hungary, India, Italy, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Switzerland, Taiwan, Ukraine, United Kingdom
• Removed Location Countries: Czech Republic

Administrative Information

• NCT Number: NCT01095003
• Other Study ID Numbers: L00070 IN 305 B0; 2008-004171-21 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Pierre Fabre Medicament
• Original Responsible Party: Jean-Claude VEDOVATO, Pierre Fabre Medicament
• Current Study Sponsor: Pierre Fabre Medicament
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Jean-Claude VEDOVATO; Pierre Fabre Medicament

• PRS Account: Pierre Fabre Medicament
• Verification Date: April 2022